| DC7575 |
10058-F4
Featured
|
10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression. |
|
| DC10075 |
10074-G5
Featured
|
10074-G5 is a c-Myc Max interaction inhibitor. |
|
| DC11918 |
CMLD010509 |
A rocaglate (flavagline) derivative that acts a highly specific inhibitor of the oncogenic translation program supporting MM, including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. |
|
| DC8664 |
APTO-253 |
APTO-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) master transcription factor, leading to cell cycle inhibition and programmed cell death. |
|
| DC10617 |
CBL0137
Featured
|
CBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM. |
|
| DC10952 |
MYCMI-6(NSC 354961)
Featured
|
MYCMI-6 (NSC354961) is a selective, high affinity inhibitor of MYC-MAX interaction, blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with Kd of 1.6 uM in SPR assay. |
|
| DC10606 |
Mycro-3
Featured
|
Mycro 3 is potent and selective for c-Myc in whole cell assays. |
|
| DC11684 |
sAJM-589 |
sAJM-589 is a novel, potent small molecule Myc inhibitor that disrupts the Myc-Max leucine-zipper heterodimer with IC50 of 1.8 uM. |
|
| DC40285 |
Lusianthridin |
Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling. |
|
| DC44757 |
EN4
Featured
|
EN4, a covalent ligand that targets cysteine 171 (C171) of MYC, is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis. |
|
| DC45348 |
NY2267 |
NY2267 is a disruptor of Myc-Max interaction, with an IC50 of 36.5 μM. |
|
| DC45837 |
MYC-IN-2 |
MYC-IN-2 is a MYC protein-protein inhibitor. MYC-IN-2 can be used for the research of cancer. |
|
| DC47701 |
c-Myc inhibitor 4 |
c-Myc inhibitor 4 is a potent, orally bioavailable c-MYC-reducing compound. |
|
| DC49807 |
c-Myc inhibitor 5 |
c-Myc inhibitor 5 (DA3) is a fluorescent, long chain-bridged bispurine that selectively targets the c-MYC G-quadruplex (KD of 16 μM). c-Myc inhibitor 5 shows inhibition on c-MYC expression rather than other G4-driven oncogenes. |
|
| DC70117 |
3JC48-3 |
3JC48-3 is a potent, cellularly active and stable c-Myc inhibitor, inhibits c-Myc-max dimerization with IC50 of 34 uM, 5 times more potent than 10074-G5, exhibits an approximate twofold selectivity for c-Myc-Max heterodimers over Max-Max homodimers.3JC48-3 inhibited the proliferation of c-Myc-over-expressing HL60 and Daudi cells with single-digit micromolar IC50 values by causing growth arrest at the G0 /G1 phase.3JC48-3 inhibited c-Myc-Max dimerization in cells validated by CoIP.3JC48-3 decreased prostate cancer cells' growth and viability in a dose-dependent fashion in vitro, upregulated PrKD1 expression and phosphorylation of known PrKD1 substrates: the threonine 120 (Thr-120) residue in beta-catenin and the serine 216 (Ser-216) in Cell Division Cycle 25 (CDC25C).3JC48-3 (1 g/kg, i.p.) decreased the rate of tumor growth in mice with patient-derived prostate cancer xenografts (PDX), without dose-limiting toxicity. |
|
| DC70398 |
F0909-0360 |
F0909-0360 is a novel small molecule inhibitor of c-Myc, causes the functional repression of c-Myc target gene, shows appreciable anticancer activity against c-Myc expressing cell lines (HT29, IC50=0.2 uM).F0909-0360 showed c-Myc dependent apoptotic cell death, efficiently inhibited the functionality of c-Myc, suppressed the expression of c-Myc target genes (CAD, ODC1, NOP58, and NOP56) both at the transcriptional and translational levels.F0909-0360 showed considerable in vitro efficacy against cancer stem cells (CSCs), inhibited sphere forming capacity of D341-CSCs with IC50 of 4.06 uM. |
|
| DC70399 |
F1021-0686 |
F1021-0686 is a novel small molecule inhibitor of c-Myc, causes the functional repression of c-Myc target gene, shows appreciable anticancer activity against c-Myc expressing cell lines (HT29, IC50=1.55 uM).F1021-0686 showed c-Myc dependent apoptotic cell death, efficiently inhibited the functionality of c-Myc, suppressed the expression of c-Myc target genes (CAD, ODC1, NOP58, and NOP56) both at the transcriptional and translational levels.F1021-0686 showed considerable in vitro efficacy against cancer stem cells (CSCs), inhibited sphere forming capacity of D341-CSCs with IC50 of 5.27 uM. |
|
| DC70631 |
MYCMI-7
Featured
|
MYCMI-7 is a small molecule MYC-binding compound (Kd=4 uM) that inhibits MYC-MAX interaction.MYCMI-7 efficiently and selectively inhibits MYC:MAX and MYCN:MAX interactions in cells, binds directly to recombinant MYC, and reduces MYC-driven transcription.MYCMI-7 induces degradation of MYC and MYCN proteins.MYCMI-7 potently induces growth arrest/apoptosis in tumor cells in a MYC/MYCN-dependent manner and downregulates the MYC pathway on a global level.MYCMI-7 downregulates MYC/MYCN, inhibits tumor growth, and prolongs survival through apoptosis in mouse tumor models of MYC-driven AML, breast cancer, and MYCN-amplified neuroblastoma. |
|
| DC70701 |
PKUMDL-YC-1205 |
PKUMDL-YC-1205 is a specific small molecule that can specifically bind to the disordered bHLH-LZ domain of c-Myc (SPR kd=18 uM).PKUMDL-YC-1205 abrogates cell proliferation of HL-60 cells with IC50 of 40 uM, blocks the interaction between c-Myc370–409 and Max. |
|
| DC70900 |
WBC100 |
WBC100 (WBC-100) is a novel potent, oral active that selectively degrades c-Myc protein over other proteins and potently kills c-Myc overexpressing cancer cell.selectively kills c-Myc overexpressing cancer cells Mia-paca2 (PDAC), H9 (T-cell lymphoma), andMOLM-13 (acute myeloid leukemia) with IC5 of 61, 17 and 16 nM, respectively.WBC100 targets the nuclear localization signal 1 (NLS1)-Basic-nuclear localization signal 2 (NLS2) region of c-Myc and induces c-Myc protein degradation through ubiquitin E3 ligase CHIP mediated 26S proteasome pathway, leading to apoptosis of cancer cells.WBC100 potently regresses multiple lethal c-Myc overexpressing tumors such as acute myeloid leukemia, pancreatic, and gastric cancers with good tolerability in multiple xenograft mouse models. |
|
| DC71559 |
IZTZ-1
Featured
|
IZTZ-1, an imidazole-benzothiazole conjugate, is a c-MYC G4 ligand. IZTZ-1 is able to downregulate the c-MYC expression by stabilizing c-MYC G4. IZTZ-1 induces cell cycle arrest, apoptosis, thereby inhibiting cell proliferation in B16 cells. IZTZ-1 shows antitumor activity, and can be used for melanoma research. |
|
| DC73810 |
D089 |
D089 is a selective small molecule stabilizer of the MYC G4-quadruplex, not only inhibits MYC expression in myeloma cell lines, but also selectively induces G1 arrest in MYC-driven cancer cell lines containing the MYC-G4 sequence. |
|
| DC73811 |
Isopomiferin |
Isopomiferin is a prenylated isoflavonoid, collapses the tumor checkpoint module (TCM) and suppresses both MYCN and TEAD4 in MYCN-amplified NBL cells. |
|
| DC73812 |
KSI-3716 |
KSI-3716 is a small molecule c-MYC inhibitor that blocks c-MYC/MAX binding to target gene promoters, inhibits c-MYC mediated transcriptional activity at concentrations as low as 1 uM. |
|
| DC73813 |
MYRA-B |
MYRA-B (NSC45641) is a small molecule that induces Myc-dependent apoptosis without affecting Myc transactivation or Myc/Max DNA binding. |
|
| DC73814 |
NSC13728 |
NSC13728 is a specific small molecule stabilizer of the Max homodimer inhibiting Myc function, also inhibits Myc-Max heterodimerization. |
|
| DC73815 |
NSC13728 hydrochloride |
NSC13728 hydrochloride is a specific small molecule stabilizer of the Max homodimer inhibiting Myc function, also inhibits Myc-Max heterodimerization. |
|
| DC73816 |
VPC-70619 |
VPC-70619 (VPC70619) is a selective small-molecule inhibitor of N-Myc transcription in NMYC transcription inhibition assays. |
|
